David A. Siegel Cellectis S.A. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.29 - $4.08 $916 - $1,632	-400 Reduced 2.61%	14,900 $34,000
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $94,405 - $194,735	-39,500 Reduced 72.08%	15,300 $43,000
Q1 2022 May 16, 2022	BUY	$3.45 - $8.77 $189,060 - $480,596	54,800 New	54,800 $249,000
Q2 2021 Aug 16, 2021	SELL	$14.36 - $20.93 $257,216 - $374,898	-17,912 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$18.19 - $33.25 $325,819 - $595,574	17,912 New	17,912 $362,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $174,458 - $231,574	-11,112 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $91,229 - $233,574	11,112 New	11,112 $198,000
Q3 2018 Nov 14, 2018	SELL	$25.99 - $30.6 $306,682 - $361,080	-11,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $327,804 - $454,654	11,800 New	11,800 $334,000

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.